Compare Credo Technology Group Holding Ltd (CRDO) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs Revvity Inc — how do they compare? Credo Technology Group Holding Ltd trades at $276.8 (market cap $46.19B), while Revvity Inc trades at $116.25 (market cap $12.91B). The key difference: Credo Technology Group Holding Ltd is far larger — about 3.6× Revvity Inc's market cap, and Revvity Inc pays a 0.24% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals.
| CRDO | RVTY | |
|---|---|---|
Market Cap | $46.19B | $12.91B |
Sector | Technology | Technology |
52-Week High | $302.52 | $117.75 |
52-Week Low | $87.81 | $82.26 |
Enterprise Value | $44.77B | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $275.98, up 15.02% in 24 hours, reflecting strong momentum. Technical indicators show a bullish trend with support at $243 and resistance at $250. The company reported robust earnings, beating estimates in Q3 2025, Q4 2025, and Q1 2026, with revenue surging 157% year-over-year in Q4 2025. Analyst consensus is strongly bullish, with 13 buy ratings and a price target of $285.42. Recent news highlights AI infrastructure demand driving growth, including contributions to the Open Compute Project.
Outlook is positive due to AI-driven demand and strong financial performance, but risks include high valuation multiples and customer concentration. The stock offers growth potential, yet investors should monitor execution risks and market volatility. Upside is supported by analyst targets, while downside protection exists near support levels.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
